PHASE 2 STUDY SUPPORTED BY A $1.6M GRANT FROM THE FDA OFFICE OF ORPHAN PRODUCT DEVELOPMENT
Therabron Therapeutics, a privately held clinical stage biopharmaceutical company, today announced that it has initiated the Phase […]
Therabron Therapeutics received a $986k, 2 year grant from the USAMRAA to evaluate its lead product, the rhCC10 protein, as a therapeutic to treat inhalation lung injury due to smoke […]
The Neonatal Drug Development Fund (NDDF) is a philanthropic research fund, created at the Floating Hospital for Children at Tufts Medical Center with the support of Therabron Therapeutics, Inc. The […]
A $1Billion tax credit/grant program, part of the 2010 federal stimulus package, was intended to bolster the biotechnology industry during the current recession. The program was administered by the IRS […]
Therabron Therapeutics’s Chief Scientist, Dr. Aprile Pilon, was invited to present a poster and to give a short presentation at a workshop entitled, “Mechanisms of Lung Injury and Immunomodulator Interventions […]
Therabron Therapeutics and the NIH’s National Cancer Institute have entered into a Cooperative Research and Development Agreement (CRADA) in order to perform research on another member of the secretoglobin family called […]